Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Drugs

Laronidase Product Approval Information - Licensing Action

Proper name: Laronidase
Tradename: Aldurazyme
Manufacturer: Biomarin Pharmaceutical Inc, Novato, CA, License #1649
Indication for Use:For patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms. The risks and benefits of treating mildly affected patients with the Scheie form have not been established. Laronidase has been shown to improve pulmonary function and walking capacity. Laronidase has not been evaluated for effects on the central nervous system manifestations of the disorder.
Approval Date: 4/30/2003
Type of submission: Biologics license application

 


Label (PDF)

Reviews
      Assay Review (PDF)
      CMC Product Review (PDF)
      Medical Officer Review (PDF)
      Review (PDF)
      Review (PDF)
      Review (PDF)
      Toxicologist's Review (PDF)

Page Last Updated: 09/30/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English